Please use this identifier to cite or link to this item:
Authors: Bu, Julia Bing
Gericke, Adrian
Pfeiffer, Norbert
Wasielica-Poslednik, Joanna
Title: Neurotrophic keratopathy : clinical presentation and effects of cenegermin
Online publication date: 2-Feb-2023
Year of first publication: 2022
Language: english
Abstract: Purpose To report on 4 patients (3 adults, 1 child) with neurotrophic keratopathy (NK) treated with cenegermin 20 μg/ml (Oxervate®), a recombinant human nerve growth factor (rhNGF), which was authorized by the European Medicines Agency for the treatment of neurotrophic keratopathy stage 2 and stage 3 of Mackie Classification in patients over 18 years of age. Observations Three patients with neurotrophic keratopathy stage 2 and 1 patient with neurotrophic keratopathy stage 3, who were treated with cenegermin eye drops 6 times daily for 8 weeks, were observed. Two patients suffered from herpetic keratitis and 2 patients from neurotrophic keratopathy secondary to orbital radiation. In addition to closure of epithelial defects, an increase of corneal sensitivity and improvement of visual acuity has been shown in all treated patients at the end of therapy. One patient reported on neuralgic pain as a side effect. The corneal epithelium remained closed during the follow-up period of 11 weeks, 31 and 32 months after cessation of therapy in 3 patients, respectively. In one patient, corneal erosion recurred 4 weeks after completion of treatment due to recurrent HSV keratitis, which resolved after therapy adjustment and the corneal epithelium remained closed for 35 weeks. Conclusion The cases presented suggest that treatment with cenegermin 20 μg/ml not only promotes corneal epithelial wound healing, but also significantly improves corneal sensitivity and visual acuity with minor side effects in adults and children.
DDC: 610 Medizin
610 Medical sciences
Institution: Johannes Gutenberg-Universität Mainz
Department: FB 04 Medizin
Place: Mainz
Version: Published version
Publication type: Zeitschriftenaufsatz
Document type specification: Scientific article
License: CC BY-NC-ND
Information on rights of use:
Journal: American journal of ophthalmology : Case reports
Pages or article number: 101488
Publisher: Elsevier
Publisher place: Amsterdam
Issue date: 2022
ISSN: 2451-9936
Publisher DOI: 10.1016/j.ajoc.2022.101488
Appears in collections:DFG-491381577-G

Files in This Item:
  File Description SizeFormat
neurotrophic_keratopathy__cli-20230126101609348.pdf1.9 MBAdobe PDFView/Open